- Home
- FCUV vs BLRX Comparison
FCUV vs BLRX Comparison
Compare FCUV & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCUV
- BLRX
- Stock Information
- Founded
- FCUV 2012
- BLRX 2003
- Country
- FCUV United States
- BLRX Israel
- Employees
- FCUV N/A
- BLRX N/A
- Industry
- FCUV Industrial Machinery/Components
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FCUV Industrials
- BLRX Health Care
- Exchange
- FCUV Nasdaq
- BLRX Nasdaq
- Market Cap
- FCUV 15.9M
- BLRX 17.1M
- IPO Year
- FCUV N/A
- BLRX 2011
- Fundamental
- Price
- FCUV $4.28
- BLRX $3.50
- Analyst Decision
- FCUV
- BLRX Strong Buy
- Analyst Count
- FCUV 0
- BLRX 2
- Target Price
- FCUV N/A
- BLRX $19.00
- AVG Volume (30 Days)
- FCUV 56.2K
- BLRX 29.2K
- Earning Date
- FCUV 11-14-2025
- BLRX 11-24-2025
- Dividend Yield
- FCUV N/A
- BLRX N/A
- EPS Growth
- FCUV N/A
- BLRX N/A
- EPS
- FCUV N/A
- BLRX N/A
- Revenue
- FCUV $432,983.00
- BLRX $17,251,000.00
- Revenue This Year
- FCUV N/A
- BLRX N/A
- Revenue Next Year
- FCUV N/A
- BLRX N/A
- P/E Ratio
- FCUV N/A
- BLRX N/A
- Revenue Growth
- FCUV 140.82
- BLRX 1.19
- 52 Week Low
- FCUV $1.80
- BLRX $2.30
- 52 Week High
- FCUV $10.90
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- FCUV 57.30
- BLRX 37.77
- Support Level
- FCUV $3.87
- BLRX $3.51
- Resistance Level
- FCUV $5.25
- BLRX $3.89
- Average True Range (ATR)
- FCUV 0.49
- BLRX 0.24
- MACD
- FCUV -0.00
- BLRX -0.04
- Stochastic Oscillator
- FCUV 54.03
- BLRX 0.00
About FCUV Focus Universal Inc.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.